Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorinostat + lenalidomide + carfilzomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Hackensack Meridian Health
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A four-drug combination regimen consisting of vorinostat (a histone deacetylase inhibitor), lenalidomide (an immunomodulatory agent), carfilzomib (a second-generation proteasome inhibitor), and dexamethasone (a corticosteroid). This combination leverages the synergistic anti-multiple myeloma activity of these agents with different mechanisms of action. The regimen has been studied in phase I clinical trials for relapsed and/or refractory multiple myeloma.
- Brand names
- ZolinzaKyprolisRevlimidDecadron
- Other names
- vorinostat-Hackensack Meridian Health-multiple myelomaQUAD regimenVorinostat combination therapy
02
Targets
GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)HDAC (HDAC family)CRBN (Cereblon)
Beyond the preview
Go deeper on vorinostat + lenalidomide + carfilzomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorinostat + lenalidomide + carfilzomib + dexamethasone.